Plasma Collection for Vaccinated Subjects
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 75A50121Q00017
- Agency
- Office of the Assistant Secretary for Preparedness and Response Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621991 Blood and Organ Banks
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
This combined synopsis/solicitation from the Department of Health and Human Services seeks plasma collection services from 35 vaccinated subjects per authorized vaccine panel. Vendors must be qualified to identify, test, and draw plasma via plasmapheresis from adults who have received either the Moderna, Pfizer, Janssen, or up to three additional vaccines authorized for emergency use under an EUA. The plasma collected must meet volume and documentation requirements and be packaged, stored at -40C, and shipped to a destination for processing into serum samples and additional testing. Award will be made to the responsible offeror with the lowest priced technically acceptable quote evaluated against the criteria specified in the solicitation. Quotes are due by April 28, 2021.
There is no set-aside designation. The primary NAICS code is 541711 and PSC code is R499. Services will be performed within the United States. Vendors must be capable of collecting plasma from 35 subjects per authorized vaccine with samples shipped within 5 days of collection for an indefinite-delivery, indefinite-quantity contract with a maximum value of $5 million over five years. Collection will occur at the vendor's licensed facility.
Notice text
As part of the Federal COVID-19 Response, the U.S. Government is establishing a new interagency COVID-19 serum biorepository that will allow for in vitro assessments of vaccine efficacy against newly emerging variants of SARS-CoV-2. In order to provide serum for the biorepository, there is an urgent need to source plasma from COVID-19-naïve subjects to have received a COVID-19 vaccine authorized for use under an Emergency Use Authorization (EUA) by the FDA.
This acquisition seeks to identify qualified vendors who are capable of identifying, testing, and drawing plasma via plasmapheresis from patients who have been vaccinated. The work must be conducted under an IRB-approved protocol. The plasma collected must meet the U.S. government’s specifications as set forth in the requirements. The plasma will then be packaged, temporarily stored, and shipped to a vendor of the U.S. Government’s choice for processing into serum. Additional retain samples must also be collected, stored, and shipped to support additional testing. A quality audit of the facility may be warranted pre-award to ensure vendor capabilities and quality controls.
See attached Combined Synopsis Solicitation for details.
Attachments
| File | Type | Posted |
|---|---|---|
| BARDA CSS 75A5012Q00017.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Plasma Collection for Vaccinated Subjects | Award Notice | |
| Plasma Collection for Vaccinated Subjects | Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity